The global lipid metabolism disease drug market is estimated to grow at a CAGR of nearly XX% during the forecast period. The key factor driving the growth of the global lipid metabolism disease drug market includes the rising prevalence of lipid metabolism disorders and increasing adoption of an unhealthy lifestyle. According to the National Organizations of Rare Disorders, in 2018, lipid metabolism disorders such as Gaucher disease accounted for the 6,000 patients in the US and accounting for more than 90% of cases among Caucasians. It is a liposomal storage disorder in which due to the lack of enzyme glucocerebrosidase, certain sugars containing fats get accumulated in the body.

Free Sample Copy @ https://www.omrglobal.com/request-sample/lipid-metabolism-disease-drug-market

The lipid metabolism disorders such as Gaucher disease, Niemann-Pick Disease, and Tay-Sachs disease, include lipids which are fats or fats-like substances including fatty acids, oils, waxes, and cholesterol. In this disorder, the body fails to convert fats into energy that subsequently leads to the accumulation of fats in the body which damages the various parts of the body including the liver, spleen, brain, peripheral nervous system, and many more. There are several FDA-approved drugs for the treatment of lipid metabolism disorders. For instance, Cerdelga (eliglustat) manufactured by Genzyme, was approved by the US FDA in 2014, for the long-term treatment of patients suffering from Gaucher disease. In the past few years, new drugs such as icosaapent ethyl, bempedoic acid, are being tested for the treatment of statin tolerated patients and has shown huge potential.

A Full Report of Global Lipid Metabolism Disease Drug Market is Available at:
https://www.omrglobal.com/industry-reports/lipid-metabolism-disease-drug-market

The key players contributing to the growth of the global lipid metabolism disease drug market by adopting various strategies such as product launches & developments, mergers and acquisition, partnerships, and agreements, include Merck Group, Novartis AG, Takeda Pharmaceutical, AstraZeneca, Boehringer Ingelheim, KOWA, Kythera, Fuji yakuhin, LG Life Science, Mitsubishi Tanabe Pharma among others. For instance, in 2019, Investigational New Drug (IND) application by IntraBio Inc. was approved by the US FDA for the clinical trial of IB1001-202 containing lead compound (IB1001) for the treatment of Tay-Sachs disease and Sandhoff Disease.

Global Lipid Metabolism Disease Drug Market – Segmentation
By Type
OTC
Rx Drugs
By Application
Lipoprotein disorders
Fatty acid oxidation defects
Mitochondrial disorders
Lysosomal storage disorders
Peroxisomal disorders
Purine and pyrimidine disorders
Porphyria’s
By Distribution Channel
Hospital
Retail Pharmacy
Online
Others

Global Lipid Metabolism Disease Drug Market – Segmentation by Region 
North America 
United States
Canada
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific 
China
Japan
India
Rest of Asia-Pacific
Rest of the World

Company Profiles
Merck KGaA
Novartis AG
Takeda Pharmaceutical Company Ltd.
AstraZeneca Plc.
Boehringer Ingelheim

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/lipid-metabolism-disease-drug-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected] 
Contact no: +91 780-304-0404